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Objectives: Anti-diabetics have varying efficacy and safety profiles. This study 
aimed to better understand patient preferences for oral anti-diabetics by examining 
the relative importance (RI) of medication attributes that influence treatment selec-
tion among patients in the US with type 2 diabetes mellitus (T2DM). MethOds: 
A web-based discrete choice experiment (DCE) was developed to assess the RI of 
7 medication attributes (effectiveness, hypoglycemia, weight change, gastrointes-
tinal/nausea side effects [SE], urinary tract infections [UTI]/genital infection SEs, 
blood pressure change, and cardiovascular risk). Participants were presented with 
2 hypothetical medications composed of varying levels of each attribute and asked 
to select the preferred profile. Part-worth utility values, or preference weights, were 
calculated to provide information on the extent to which participants preferred 
one level of an attribute over another and used to derive RI values. RI values were 
calculated based upon the relative weight of each attribute in the sum of part-worth 
utility values, with higher values indicating greater importance. Results: A total 
of 809 invitations were sent; 54% responded. The final sample was composed of 
the first 200 eligible participants with self-reported T2DM (50% male, mean age 
60.9 years). The RI values for the attributes in order of importance were effective-
ness (25.9%), hypoglycemic events (21.5%), weight change (21.0%), gastrointestinal/
nausea SEs (14.1%), UTI/genital infection SEs (11.0%), blood pressure (3.7%), and 
cardiovascular risk (2.9%). Effectiveness, hypoglycemic events, and weight change 
comprised 68.4% of the RI. cOnclusiOns: Results suggest that effectiveness, hypo-
glycemic events, and weight change are the predominant influences on patients’ 
medication decisions for T2DM. These results were consistent with findings from 
a DCE conducted in the United Kingdom (UK), which utilized a similar methodol-
ogy and yielded similar RI results. The confluence of these findings highlights the 
importance of these attributes as drivers of medication decisions in patients with 
T2DM in the United States and UK.
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Objectives: To elicit preferences of injection-naïve patients with type 2 diabetes 
mellitus (T2DM) for features of glucagon-like peptide-1 receptor agonist (GLP-1RA) 
injections using a discrete-choice experiment; to test for effect of injection fre-
quency on patient preferences. MethOds: Injection-naïve adults in the United 
States with self-reported physician diagnosis of T2DM completed a web-enabled, 
discrete-choice experiment (DCE). The survey presented patients with a series 
of 10 choice questions, each including a pair of hypothetical GLP-1RA injection 
profiles with equivalent efficacy and side effects. Each profile was defined by the 
following pre-determined attributes identified from patient interviews: frequency 
of injections (weekly, daily), injection device (multiple-use injection pen, single-
use injection pen, single-use vial and syringe), needle size (shorter and thinner, 
longer and thicker), need for refrigeration, and injection-site nodules. Choice ques-
tions were based on a pre-determined experimental design with known statisti-
cal properties allowing for interaction effects between injection frequency and 
other injection features. Random-parameters logit was used to estimate pref-
erences. Results: A total of 184 respondents completed the survey; 50% were 
women and mean age (SD) was 60.8 (11.0) years. Injection frequency was the most 
important attribute compared with all other attributes in the DCE. Preferences 
for all injection features were dependent on frequency of injections; that is, the 
estimated preference parameter on the interaction between injection frequency 
and each treatment feature was statistically significant. Negative injection fea-
tures were statistically significantly less important to patients if injections were 
weekly instead of daily. For all possible injection profiles included in the design, a 
greater proportion of patients preferred a weekly injection compared with a daily 
injection. cOnclusiOns: In this study, several device attributes were suggested 
to predict treatment choice in injection-naïve T2DM patients. Results suggest that 
injection frequency is of primary importance and key to understanding patient 
preferences for injectable diabetes treatments.
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Objectives: The objective of this study was to estimate the effect of both diabetes 
related symptoms, outcomes and concomitant conditions on the HRQoL as reported 
by diabetes patients. MethOds: A cross-sectional survey of diabetes patients (n 
= 1480) living in the United States. Each patient completed a questionnaire, which 
included the EQ-5D-5L instrument and accompanying VAS. Patients were also asked 
to state which diabetes symptoms and concomitant conditions they are suffering 
from. By means of logistic linear modeling the health utility scores derived from 
the EQ-5D-5L were linked to symptoms and concomitant conditions. Results: All 
tested diabetes symptoms and concomitant conditions together explain up to 52% 
of the variation in health utility scores (R² = 0,52). Out of 35 tested symptoms and 
concomitant conditions, 8 had a significant negative impact on HRQoL ( p-value < 
0,001). Ranked in order of standardized β -value these are: depression (β -value: -0,25), 
arthritis (β -value: -0,21), neuropathy (β -value: -0,16), (mini)-stroke (β -value: -0,11), 
blood circulation problems (β -value: -0,09), pain in hands or feet (β -value: -0,09), 
foot sores and ulcers (β -value: -0,08), and high blood pressure (β -value: -0,07). For 
all other symptoms or concomitant conditions lower levels of significance were 
found. cOnclusiOns: Diabetes related symptoms and concomitant conditions are 
a significant driver of reduced levels of HRQoL. Depression and arthritis are the two 
concomitant conditions with the highest negative impact on HRQoL.
diabetes mellitus (T2DM). MethOds: Patients 18 years and older diagnosed with 
T2DM who had at least one indexed claim from May 2009 through September 2010 
were assessed from the Truven Health MarketScan Research Database. Inclusion 
required 1 year continuous enrollment pre and post-index insulin claim with ≤ 
1 prescription for an oral anti-diabetic drug during the pre-index period. Patients 
diagnosed with T1DM or using specialty self-injectables during the pre-index period 
were excluded. Patients were grouped into three PN length cohorts: short (4 & 5mm), 
intermediate (6mm) and long (8 & 12.7mm) needle initiators. Persistence was evalu-
ated at 6 and 12 months by the absence of 90 day gaps between insulin prescriptions. 
Differences in persistence between cohorts were compared for statistical signifi-
cance using a Fisher’s exact test (95% CI, two-tail). Results: The study included 21,622 
patients with an average age of 59.1 years (SD= 11.4). Most patients were within the 
long needle group (67.6%); followed by the short (21.5%) and intermediate (10.8%) 
needle users. The majority of patients were non-persistent at the end of the first 
year of insulin use, with only 38.4% being persistent. Within the first 6 months only 
46.5% of patients were found to be persistent. However, of those patients who were 
persistent within first 6 months, the likelihood of them remaining persistent was 
high with 82.6% of users reporting no gaps at 1 year. When examining the correlation 
between needle length and persistence, short needle users were 4.9% (p< 0.001) and 
2.7% (p= 0.001) more persistent at 6 months than intermediate and long needle users, 
respectively. cOnclusiOns: Persistence rates were higher for those patients using 
shorter needles, particularly early on at earlier phases of insulin adoption.
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Objectives: Although health status among patients with type 2 diabetes (T2D) in 
Japan can be improved with advances in treatment, there are other modifiable fac-
tors which could also be examined as potential targets for intervention. This study 
examined the association of adherence and health behaviors with health status in 
this population. MethOds: Data from the Japan 2012 National Health and Wellness 
Survey (NHWS) were used (N= 30,000). Only respondents who reported a diagnosis of 
T2D and who were currently using a prescription medication were included (n= 892). 
Smoking, exercise behavior, obesity, alcohol use, and medication adherence (meas-
ured using the MMAS-8) were used as predictors of health status (measured using 
the SF-36v2) controlling for demographics and comorbidities. Results: 79.7% of 
respondents were male; the mean age was 62.2 years. Nearly two-thirds of patients 
had a history of smoking (23.4% were current smokers and 41.9% were former smok-
ers) and over a quarter consumed alcohol daily. Patients exercised a mean of 8 days 
per month and over 40% of patients were either overweight (29.4%) or obese (11.4%). 
Forgetfulness was the most common reason for non-adherence with medication 
(forgetting, 49.4%; difficulty remembering, 32.8%; forgetting when traveling/leav-
ing home, 30.8%). Controlling for demographics and comorbidities, the strongest 
predictors of health status were with smoking (b = -1.62 for PCS), obesity (b = -3.16 
for PCS), exercise (b = 0.15 for PCS), and not taking medications the prior day (b = 
-1.85 for PCS) (all p< .05). cOnclusiOns: Smoking cessation, improved exercise and 
weight reduction may result in significant health status improvements, aside from 
their well-known clinical benefits. Although forgetting medication was common 
among patients with T2D, the very act of taking or not taking medication the day 
before was predictive of physical health status. Interventions which can improve 
adherence rates could also have significant health status benefits.
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Objectives: Weight satisfaction (WS) has been shown to be associated with posi-
tive health behaviors important for optimal management of type 2 diabetes mel-
litus (T2DM). In a previously reported study of CANA vs. PBO in triple therapy with 
metformin and sulfonylurea in addition to background diet and exercise, CANA was 
associated with significant reduction in body weight vs. PBO at 26 weeks, with an 
absolute mean weight loss of up to -2.52 kg (SE = 0.29). The objective of this analy-
sis was to explore the direction and strength of the relationship between weight 
change and change in WS using data from this trial. MethOds: The Current Health 
Satisfaction Questionnaire was administered at baseline and over time to capture 
agreement with a statement about WS. Subjects were re-classified into 2 catego-
ries at baseline, satisfied or dissatisfied/neutral, based upon responses to a 7-point 
Likert-style scale. Differences in least square (LS) mean change in weight by changes 
in WS after 26 weeks were compared regardless of treatment using ANCOVA models 
and adjusted for selected baseline covariates (i.e., weight, age, and gender). Logistic 
regression, adjusted for the same covariates, was used to generate odds ratios (OR) 
for changes in WS associated with weight change. Results: Of the subjects in the 
study (n = 386), 75.6% were dissatisfied/neutral with their body weight at baseline. 
Subjects with improved WS lost more weight on average than those with no WS 
improvement (difference in LS means = -1.52 kg [95% CI: -2.68, -0.36]). Weight loss 
of 3kg was associated with a 54% greater chance of an improvement in WS from 
dissatisfied/neutral to satisfied (OR = 1.54; 95% CI: 1.15, 2.05). cOnclusiOns: These 
results suggest that an amount of weight loss in the range achieved by subjects tak-
ing CANA is noticeable and important to people living with T2DM.
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